Delaware
(State
or jurisdiction
of
incorporation or organization)
|
2834
(Primary
Standard Industrial
Classification
Code Number)
|
58-1486040
(I.R.S.
Employer
Identification
No.)
|
||
180
Mount Airy Road, Suite 102
Basking
Ridge, NJ 07920
(Address
and telephone number of principal executive offices and principal
place of
business)
|
||||
Michael
D. Becker
Chief
Executive Officer
VioQuest
Pharmaceuticals, Inc.
180
Mount Airy Road, Suite 102
Basking
Ridge, NJ 07920
Telephone:
(908)
766-4400
Facsimile:
(908)
766-4455
(Name,
address and telephone number of agent for service)
|
Copies
to:
William
M. Mower, Esq.
Maslon
Edelman Borman & Brand, LLP
90
South 7th Street, Suite 3300
Minneapolis,
Minnesota 55402
Telephone:
(612) 672-8200
Facsimile:
(612) 672-8397
|
Large accelerated filer o
|
Accelerated filer o
|
Non-accelerated filer o
|
Smaller reporting company x
|
|
Page
|
Prospectus
Summary
|
4
|
Description of Private Placement of Preferred Stock |
9
|
Risk
Factors
|
12
|
Note
Regarding Forward Looking Statements
|
18
|
Use
of Proceeds
|
18
|
Selling
Stockholders
|
19
|
Prior Transactions between the Company and the Selling Shareholders |
22
|
Plan
of Distribution
|
25
|
Description
of Capital Stock
|
27
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
31
|
Description
of Business
|
44
|
Management
and Board of Directors
|
57
|
Security
Ownership of Certain Beneficial Owners and Management
|
68
|
Transactions
with Related Persons, Promoters and Certain Control
Persons
|
69
|
Material
Changes
|
70
|
Where
You Can Find More Information
|
70
|
Validity
of Common Stock
|
70
|
Experts
|
70
|
Disclosure
Of Commission Position On Indemnification For Securities Act
Liabilities
|
70
|
Financial
Statements
|
F-1
|
·
|
243,397
shares of our common stock issuable at a price of $4.00 per share
upon
exercise of warrants issued to the investors in our 2007 private
placement
of our convertible promissory notes;
|
·
|
5,774,167
shares of our common stock underlying 3,464.5 shares of our Series
A
Convertible Preferred Stock convertible at a price of $0.60 per share
issued to the investors in our private placement of Series A Convertible
Preferred stock;
|
·
|
2,887,083
shares of our common stock issuable at a price of $1.00 per share
upon the
exercise of warrants issued to the investors in our private placement
of
Series A Convertible Preferred stock;
|
·
|
896,096
shares of our common stock underlying 3,405.165 shares of our Series
B
Convertible Preferred Stock convertible at a price of $3.80 per share
as
issued to our former note holders upon the conversion of the note’s
principal and accrued interest into shares of our Series B Convertible
Preferred Stock;
|
·
|
492,416
shares of our common stock issuable at a price of $0.80 per share
upon the
exercise of warrants issued to the placement agents in connection
with our
private placement of Series A Preferred Stock.
|
·
|
120,250 shares of our common stock issuable at a price of $4.20 per share upon the exercise of warrants issued to the placement agents in connection with our private placement of our convertible promissory notes. |
Common
stock offered
|
10,413,409 shares
|
|
|
Common
stock outstanding before the offering(1)
|
5,461,644 shares
|
|
Common
stock outstanding after the offering(2)
|
15,875,053
shares
|
|
Common
Stock OTC Bulletin Board symbol
|
VOQP.OB
|
(1)
|
Based
on the number of shares outstanding as of May 19, 2008, not including
2,738,382 shares issuable upon exercise of various warrants and options
to
purchase common stock.
|
(2) |
Assumes
the issuance of all shares offered hereby that are issuable upon
exercise
of warrants.
|
Series
A Convertible Preferred Stock
|
Market Price of
Common Stock
on April 8,
2008*
|
Fixed
Conversion
Price of Series
A Stock
|
Total Number of
Shares of Common
Stock Underlying
Series A Stock
|
Total Market Price of
Shares Underlying
Series A Stock
|
Aggregate
Conversion Price
of Shares at Fixed
Conversion Price
|
Total Discount
for Series A
Purchasers
|
||||||||||||
$
|
0.80
|
$
|
0.60
|
5,774,167
|
$
|
4,619,333.60
|
$
|
3,464,500.20
|
$
|
1,154,833.40
|
Series
B Convertible Preferred
Stock
|
Market Price of
Common Stock
on March 13,
2008*
|
Fixed
Conversion
Price of Series
B Stock
|
Total Number of
Shares of Common
Stock Underlying
Series B Stock
|
Total Market Price of
Shares Underlying
Series B Stock
|
Aggregate
Conversion Price
of Shares at Fixed
Conversion Price
|
Total Premium
for Series B
Purchasers
|
||||||||||||
$
|
0.80
|
$
|
3.80
|
896,096
|
$
|
716,876.80
|
$
|
3,405,164.80
|
$ |
2,688,288
|
|
Aggregate Gross
Proceeds
|
Placement Agent Fees
and Commissions
|
Aggregate Net
Proceeds to Company
|
Total Discount for
Series A Purchasers
|
Net Proceeds Less
Total Discount for
Series A Purchasers
|
||||||||||
$
|
2,959,500
|
$
|
242,000
|
$
|
2,717,500
|
$
|
1,154,833.40
|
$
|
1,562,666.60
|
Senior
Convertible Promissory
Notes
|
Aggregate Gross Proceeds
|
Placement Agent Fees and Commissions
|
Aggregate Net Proceeds to Company
|
||||||
$
|
3,700,000
|
$
|
256,025
|
$
|
3,443,975
|
Investor
Name
|
Amount of
Convertible Promissory Note
|
Accrued Interest
Through March
13, 2008
|
Shares of Series
B Convertible Preferred
Stock Received Upon
Note Conversion
|
|||||||
Neel
B. Ackerman and Martha N. Ackerman
|
$
|
200,000.00
|
$
|
11,396
|
211.396
|
|||||
Vincent
M. Aita
|
$
|
10,000.00
|
$
|
570
|
10.570
|
|||||
Jesus
A. Anaya
|
$
|
25,000.00
|
$
|
1,402
|
26.402
|
|||||
Lucille
S. Ball Irrevocable Trust, Richard L. Clarkson, Trustee
|
$
|
85,000.00
|
$
|
4,766
|
89.766
|
|||||
Lee
P. Bearsch
|
$
|
50,000.00
|
$
|
2,803
|
52.803
|
|||||
David
Benadum
|
$
|
20,000.00
|
$
|
1,140
|
21.140
|
|||||
Frank
Calcutta
|
$
|
150,000.00
|
$
|
8,547
|
158.547
|
|||||
Duane
Clarkson
|
$
|
65,000.00
|
$
|
3,644
|
68.644
|
|||||
Clarkson
Trust, Richard L. Clarkson, Trustee
|
$
|
50,000.00
|
$
|
2,803
|
52.803
|
|||||
Cranshire
Capital, LP
|
$
|
250,000.00
|
$
|
14,017
|
264.017
|
|||||
CSA
Biotechnology Fund I, LLC
|
$
|
1,250,000.00
|
$
|
71,228
|
821.228
|
(1)
|
||||
Michael
Cushing
|
$
|
50,000.00
|
$
|
2,803
|
52.803
|
|||||
Ennino
DePianto
|
$
|
25,000.00
|
$
|
1,402
|
26.402
|
|||||
Praful
Desai
|
$
|
75,000.00
|
$
|
4,273
|
79.273
|
|||||
Gregg
Dovolis
|
$
|
75,000.00
|
$
|
4,273
|
79.273
|
|||||
John
O. Dunkin
|
$
|
50,000.00
|
$
|
2,849
|
52.849
|
|||||
Franz
Family Trust, David and Nicole Franz, Trustees
|
$
|
25,000.00
|
$
|
1,424
|
26.424
|
|||||
Stephen
Gerber
|
$
|
100,000.00
|
$
|
5,698
|
105.698
|
|||||
Daniel
E. Greenleaf
|
$
|
17,500.00
|
$
|
997
|
18.497
|
|||||
Robert
Guercio
|
$
|
75,000.00
|
$
|
4,273
|
79.273
|
|||||
Robert
Joseph
|
$
|
25,000.00
|
$
|
1,402
|
26.402
|
|||||
Ronald
P. Laurain
|
$
|
25,000.00
|
$
|
1,424
|
26.424
|
|||||
Stephen
H. Lebovitz
|
$
|
25,000.00
|
$
|
1,424
|
26.424
|
|||||
Brian
Lenz
|
$
|
5,000.00
|
$
|
285
|
.285
|
(2)
|
||||
S.
Alan Lisenby
|
$
|
150,000.00
|
$
|
8,547
|
158.547
|
|||||
Joe
Nitti
|
$
|
10,000.00
|
$
|
561
|
10.561
|
|||||
Thomas
& Denise M. Nudo
|
$
|
225,000.00
|
$
|
12,820
|
237.820
|
|||||
Alan
Platner
|
$
|
25,000.00
|
$
|
1,402
|
26.402
|
|||||
David
Pudelsky & Nancy Pudelsky
|
$
|
30,000.00
|
$
|
1,709
|
31.709
|
|||||
Louis
R. Reif
|
$
|
80,000.00
|
$
|
4,558
|
84.558
|
|||||
Suzanne
Schiller
|
$
|
25,000.00
|
$
|
1,424
|
26.424
|
|||||
George
L. Seward
|
$
|
25,000.00
|
$
|
1,402
|
26.402
|
|||||
Jerome
Shinkay
|
$
|
25,000.00
|
$
|
1,424
|
26.424
|
|||||
William
Silver
|
$
|
25,000.00
|
$
|
1,424
|
26.424
|
|||||
Vernon
L. Simpson
|
$
|
25,000.00
|
$
|
1,402
|
26.402
|
|||||
Lucile
Slocum
|
$
|
80,000.00
|
$
|
4,558
|
84.558
|
|||||
Pershing
LLC as Custodian for Howard M. Tanning
|
$
|
125,000.00
|
$
|
7,122
|
132.122
|
|||||
Carolyn
Taylor
|
$
|
100,000.00
|
$
|
5,698
|
105.698
|
|||||
Michael
Weiser
|
$
|
10,000.00
|
$
|
570
|
10.570
|
|||||
M.H.
Yokoyama & J.S. Venuti Family Trust dated 4/95
|
$
|
12,500.00
|
$
|
701
|
13.201
|
(1) |
CSA
Biotechnology Fund I, LLC, invested $500,000 in our private
placement of
the Series A Convertible Preferred Stock and, pursuant to
the terms of the
Series B Convertible Preferred Stock, converted an amount
equal to such
investment on a dollar-for-dollar basis from Series B Convertible
Preferred Stock into Series A Preferred Stock. Thus, CSA
Biotechnology
Fund’s number of shares of Series B Convertible Preferred Stock
was
reduced by the amount converted into Series A Convertible
Preferred
Stock.
|
(2) |
Brian
Lenz, our Former Chief Financial Officer, invested $5,000
in our private
placement of Series A Convertible Preferred Stock and, pursuant
to the
terms of the Series B Convertible Preferred Stock, converted
an amount
equal to such investment on a dollar-for-dollar basis from
Series B
Convertible Preferred Stock into Series A Preferred Stock.
Thus, Mr.
Lenz’s number of shares of Series B Convertible Preferred Stock
was
reduced by the amount converted into Series A Convertible
Preferred
Stock.
|
•
|
the
terms of our license agreements pursuant to which we obtain the right
to
develop and commercialize drug candidates, including the amount of
license
fees and milestone payments required under such
agreements;
|
•
|
the
results of any clinical trials;
|
•
|
the
scope and results of our research and development
programs;
|
•
|
the
time required to obtain regulatory
approvals;
|
•
|
our
ability to establish and maintain marketing alliances and collaborative
agreements; and
|
•
|
the
cost of our internal marketing
activities.
|
•
|
acquire
the rights to develop and commercialize a drug
candidate;
|
•
|
undertake
pre-clinical development and clinical trials for drug candidates
that we
acquire;
|
•
|
seek
regulatory approvals for drug
candidates
|
•
|
implement
additional internal systems and
infrastructure;
|
•
|
lease
additional or alternative office facilities;
and
|
•
|
hire
additional personnel.
|
•
|
delay
commercialization of, and our ability to derive product revenues
from, a
drug candidate;
|
•
|
impose
costly procedures on us; and
|
•
|
diminish
any competitive advantages that we may otherwise
enjoy.
|
•
|
unforeseen
safety issues;
|
•
|
determination
of dosing issues;
|
•
|
lack
of effectiveness during clinical
trials;
|
•
|
slower
than expected rates of patient
recruitment;
|
•
|
inability
to monitor patients adequately during or after treatment;
and
|
•
|
inability
or unwillingness of medical investigators to follow our clinical
protocols.
|
•
|
perceptions
by members of the health care community, including physicians, about
the
safety and effectiveness of our
drugs;
|
•
|
cost-effectiveness
of our product relative to competing
products;
|
•
|
availability
of reimbursement for our products from government or other healthcare
payers; and
|
•
|
effectiveness
of marketing and distribution efforts by us and our licensees and
distributors, if any.
|
•
|
We
may be unable to identify manufacturers on commercially reasonable
terms
or at all because the number of potential manufacturers is limited
and the
FDA must approve any replacement contractor. This approval would
require
new testing and compliance inspections. In addition, a new manufacturer
would have to be educated in, or develop substantially equivalent
processes for, production of our products after receipt of FDA approval,
if any.
|
•
|
Our
third-party manufacturers might be unable to formulate and manufacture
our
drugs in the volume and of the quality required to meet our clinical
needs
and commercial needs, if any.
|
•
|
Our
future contract manufacturers may not perform as agreed or may not
remain
in the contract manufacturing business for the time required to supply
our
clinical trials or to successfully produce, store and distribute
our
products.
|
•
|
Drug
manufacturers are subject to ongoing periodic unannounced inspection
by
the FDA, the DEA, and corresponding state agencies to ensure strict
compliance with good manufacturing practice and other government
regulations and corresponding foreign standards. We do not have control
over third-party manufacturers’ compliance with these regulations and
standards.
|
•
|
If
any third-party manufacturer makes improvements in the manufacturing
process for our products, we may not own, or may have to share, the
intellectual property rights to the
innovation.
|
•
|
developing
drugs;
|
•
|
undertaking
pre-clinical testing and human clinical
trials;
|
•
|
obtaining
FDA and other regulatory approvals of
drugs;
|
•
|
formulating
and manufacturing drugs; and
|
•
|
launching,
marketing and selling drugs.
|
•
|
announcements
of technological innovations or new commercial products by our competitors
or us;
|
•
|
developments
concerning proprietary rights, including
patents;
|
•
|
regulatory
developments in the United States and foreign
countries;
|
•
|
economic
or other crises and other external
factors;
|
•
|
period-to-period
fluctuations in our revenues and other results of
operations;
|
•
|
changes
in financial estimates by securities analysts;
and
|
•
|
sales
of our common stock.
|
Selling
Stockholder
|
Shares
Beneficially Owned Before
Offering
|
Number
of Shares of Common Stock
Issuable Upon:
|
Percentage
Beneficial Ownership After
Offering
|
|
Conversion
of Series B Convertible
Preferred
Stock
|
Warrants
+
|
|||
Neel
B. Ackerman and Martha N. Ackerman
|
110,376
(1)
|
55,630
|
13,157
|
*
|
Vincent
M. Aita
|
31,009
(2)
|
2,781
|
657
|
*
|
Jesus
A. Anaya
|
8,591
|
6,947
|
1,644
|
-
|
Lucille
S. Ball Revocable Trust (a)
|
29,214
|
23,622
|
5,592
|
|
Lee
P. Bearsch
|
17,184
|
13,895
|
3,289
|
-
|
David
Benadum
|
20,486
(3)
|
5,563
|
1,315
|
*
|
Frank
Calcutta
|
66,710
(4)
|
41,722
|
9,868
|
*
|
Duane
Clarkson
|
22,340
|
18,064
|
4,276
|
-
|
Clarkson
Trust (b)
|
46,399
|
13,895
|
3,289
|
-
|
Cranshire
Capital, LP (c)
|
111,087
(5)
|
69,478
|
16,447
|
*
|
CSA
Biotechnology Fund I, LLC (d)
|
1,965,014
(6)
|
216,112
|
82,236
|
*
|
Michael
Cushing
|
17,184
|
13,895
|
3,289
|
-
|
Ennino
DePianto
|
16,151
(7)
|
6,947
|
1,644
|
*
|
Praful
Desai
|
32,599
(8)
|
20,861
|
4,934
|
*
|
Gregg
Dovolis
|
32,599
(8)
|
20,861
|
4,934
|
*
|
John
O. Dunkin
|
30,804
(3)
|
13,907
|
3,289
|
*
|
Franz
Family Trust (e)
|
8,597
|
6,953
|
1,644
|
-
|
Stephen
Gerber
|
34,393
|
27,815
|
6,578
|
-
|
Daniel
E. Greenleaf
|
189,512
(9)
|
4,867
|
1,151
|
-
|
Robert
Guercio
|
39,403
(3)
|
20,861
|
4,934
|
*
|
Robert
Joseph
|
8,591
|
6,947
|
1,644
|
-
|
Ronald
P. Laurain
|
8,597
|
6,953
|
1,644
|
-
|
Stephen
H. Lebovitz
|
8,597
|
6,953
|
1,644
|
-
|
Brian
Lenz
|
80,238(10)
|
75
|
328
|
*
|
S.
Alan Lisenby
|
78,806
(11)
|
41,722
|
9,868
|
*
|
M.H.
Yokoyama & J.S. Venuti Family Trust dated 4/95 (f)
|
4,295
|
3,473
|
822
|
-
|
Joe
Nitti
|
3,436
|
2,779
|
657
|
-
|
Thomas
& Denise M. Nudo
|
77,386
|
62,584
|
14,802
|
-
|
Alan
Platner
|
18,149
(12)
|
6,947
|
1,644
|
*
|
David
Pudelsky & Nancy Pudelsky
|
21,657
(13)
|
8,344
|
1,973
|
*
|
Louis
R. Reif
|
54,731
(9)
|
22,252
|
5,263
|
*
|
Suzanne
Schiller
|
15,401
(7)
|
6,953
|
1,644
|
*
|
George
L. Seward
|
8,591
|
6,947
|
1,644
|
-
|
Jerome
Shinkay
|
8,597
|
6,953
|
1,644
|
-
|
William
Silver
|
15,401
(7)
|
6,953
|
1,644
|
*
|
Vernon
L. Simpson
|
8,591
|
6,947
|
1,644
|
-
|
Lucile
Slocum
|
42,635
(4)
|
22,252
|
5,263
|
*
|
Pershing
LLC as Custodian for Howard M. Tanning
|
84,571
(1)
|
34,768
|
8,223
|
*
|
Carolyn
Taylor
|
43,4635(14)
|
27,815
|
6,578
|
*
|
Michael
Weiser
|
230,497
(15)
|
2,781
|
657
|
1.8
|
Lindsay
A. Rosenwald
|
636,002 (16)
|
-
|
12,105
|
4.0
|
GunnAllen
Financial, Inc.
|
75,250
|
-
|
75,250
|
-
|
Harris
Lydon
|
292,270
(17)
|
-
|
32,895
|
-
|
Selling
Stockholder
|
Shares
Beneficially Owned Before
Offering
|
Number
of Shares of Common Stock
Issuable Upon:
|
||
Conversion
of Series A Convertible
Preferred
Stock
|
Exercise
of
Warrants
+
|
Percentage Beneficial
Ownership After Offering
|
||
AB
Capital, L.P.
(g)
|
150,000
|
100,000
|
50,000
|
-
|
Adams
Market Neutral, LLLP(h)
|
75,000
|
50,000
|
25,000
|
-
|
Fernando
Ahumada
|
107,466(18)
|
66,667
|
33,333
|
*
|
Jorge
Ahumada
|
59,332(19)
|
33,333
|
16,667
|
*
|
Balanced
Investment
|
220,833
|
125,000
|
62,500
|
*
|
Alp
Benadrete
|
56,250
|
37,500
|
18,750
|
-
|
Izzet
Benadrete
|
125,000
|
83,333
|
41,667
|
-
|
Capretti
Grandi, LLC(i)
|
1,375,000(20)
|
833,333
|
416,667
|
-
|
Tim
P. Cooper
|
50,000
|
33,333
|
16,667
|
-
|
Russell
H. Ellison
|
25,000
|
16,667
|
8,333
|
-
|
Boulevard
Georges
|
170,000
|
113,333
|
56,667
|
-
|
Steven
T. Glass
|
62,500
|
41,667
|
20,833
|
-
|
Ben
Heller
|
200,000
|
133,333
|
66,667
|
-
|
Elliot
H. Herskowitz IRA Rollover
|
154,156(21)
|
83,333
|
41,667
|
*
|
Neil
Herskowitz IRA Rollover
|
162,434(22)
|
83,333
|
41,667
|
*
|
High
Glen Properties Limited(k)
|
250,000
|
166,667
|
83,333
|
-
|
David
Jaroslawicz
|
208,000(23)
|
133,333
|
66,667
|
*
|
Daniel
U. Kelves & BettyAnn Kelves
|
15,833
|
8,333
|
4,167
|
*
|
Charles
Hartman King
|
62,500
|
41,667
|
20,833
|
-
|
CSA
Biotechnology Fund II, LLC(l)
|
1,965,014
(6)
|
1,666,667
|
833,333
|
*
|
Klaus
Kretschmer
|
500,000
|
333,334
|
166,667
|
-
|
Nicholas
B. Kronwall Trust Dated 11/12/69
|
42,133
|
16,667
|
8,333
|
*
|
Brian
Lenz
|
53,571
(9)
|
16,667
|
8,333
|
*
|
Javier
Livas
|
25,000
|
16,667
|
8,333
|
-
|
Harris
Lydon
|
292,270(17)
|
16,667
|
8,333
|
*
|
Susan
and Harry Newton, JTWROS
|
125,000
|
83,333
|
41,667
|
-
|
Mario
Pasquel and Begona Miranda
|
32,388(24)
|
16,667
|
8,333
|
*
|
Neal
Polan
|
62,500
|
41,667
|
20,833
|
-
|
Elke
R de Ramirez
|
28,312(25)
|
16,667
|
8,333
|
*
|
Riverside
Contracting, LLC(m)
|
402,156(26)
|
250,000
|
125,000
|
*
|
Robert
Roth
|
25,000
|
16,667
|
8,333
|
-
|
Roberto
Segovia
|
27,004
|
15,000
|
7,500
|
*
|
South
Ferry #2 LP(n)
|
1,316,666
|
833,333
|
416,667
|
*
|
Starlight
Investment Holdings Limited(o)
|
250,000
|
166,667
|
83,333
|
*
|
Tokenhouse
Trading PTE Ltd.(p)
|
183,915(27)
|
83,333
|
41,667
|
*
|
Lindsay
A. Rosenwald
|
626,002(16)
|
-
|
251,666
|
4.0
|
Karl
Ruggeberg
|
40,667
|
-
|
40,667
|
-
|
Julstin
Welling
|
1,667
|
-
|
1,667
|
-
|
Ece
Marcelli
|
23,416
|
-
|
23,416
|
-
|
CURRENT
TRANSACTION
|
PRIOR
TRANSACTIONS
|
|||||||||||||||||||||||||||||||||
Name
|
Shares
Beneficially Owned Before Offering
|
Conversion
of Series B Convertible Preferred Stock
|
No.
of Shares Issuable upon Exercise of Warrants
|
Transaction
|
Shares
Beneficially Owned Before Offering
|
Common
Stock
|
No.
of Shares Issuable upon Exercise of Warrants
|
Transaction
|
Shares
Beneficially Owned Before Offering
|
Common
Stock
|
No.
of Shares Issuable upon Exercise of Warrants
|
|||||||||||||||||||||||
Neel
B. Ackerman and Martha N. Ackerman
|
110,376
|
55,630
|
13,157
|
C
|
41,580
|
30,800
|
10,780
|
|||||||||||||||||||||||||||
Vincent
M. Aita
|
31,009
|
2,781
|
657
|
|||||||||||||||||||||||||||||||
Jesus
A. Anaya
|
8,591
|
6,947
|
1,644
|
|||||||||||||||||||||||||||||||
Lucille
S. Ball Revocable Trust
|
29,214
|
23,622
|
5,592
|
|||||||||||||||||||||||||||||||
Lee
P. Bearsch
|
17,184
|
13,895
|
3,289
|
|||||||||||||||||||||||||||||||
David
Benadum
|
20,486
|
5,563
|
1,315
|
C
|
13,608
|
10,080
|
3,528
|
|||||||||||||||||||||||||||
Frank
Calcutta
|
66,710
|
41,722
|
9,868
|
C
|
15,120
|
11,200
|
3,920
|
|||||||||||||||||||||||||||
Duane
Clarkson
|
22,340
|
18,064
|
4,276
|
|||||||||||||||||||||||||||||||
Clarkson
Trust
|
46,399
|
13,895
|
3,289
|
|||||||||||||||||||||||||||||||
Cranshire
Capital, LP
|
111,087
|
69,478
|
16,447
|
A
|
25,163
|
14,496
|
10,666
|
|||||||||||||||||||||||||||
CSA
Biotechnology Fund, LLC
|
1,965,014
|
216,112
|
82,236
|
|||||||||||||||||||||||||||||||
Michael
Cushing
|
17,184
|
13,895
|
3,289
|
|||||||||||||||||||||||||||||||
Ennino
DePianto
|
16,151
|
6,947
|
1,644
|
C
|
7,560
|
5,600
|
1,960
|
|||||||||||||||||||||||||||
Praful
Desai
|
32,599
|
20,861
|
4,934
|
C
|
6,804
|
5,040
|
1,764
|
|||||||||||||||||||||||||||
Gregg
Dovolis
|
32,599
|
20,861
|
4,934
|
C
|
6,804
|
5,040
|
1,764
|
|||||||||||||||||||||||||||
John
O. Dunkin
|
30,804
|
13,907
|
3,289
|
C
|
13,608
|
10,080
|
3,528
|
|||||||||||||||||||||||||||
Franz
Family Trust
|
8,597
|
6,953
|
1,644
|
|||||||||||||||||||||||||||||||
Stephen
Gerber
|
34,393
|
27,815
|
6,578
|
|||||||||||||||||||||||||||||||
Daniel
E. Greenleaf
|
189,512
|
4,867
|
1,151
|
|||||||||||||||||||||||||||||||
Robert
Guercio
|
39,403
|
20,861
|
4,934
|
C
|
13,608
|
10,080
|
3,528
|
|||||||||||||||||||||||||||
Robert
Joseph
|
8,591
|
6,947
|
1,644
|
|||||||||||||||||||||||||||||||
Ronald
P. Laurain
|
8,597
|
6,953
|
1,644
|
|||||||||||||||||||||||||||||||
Stephen
H. Lebovitz
|
8,597
|
6,953
|
1,644
|
|||||||||||||||||||||||||||||||
Brian
Lenz
|
53,571
|
75
|
328
|
|||||||||||||||||||||||||||||||
S.
Alan Lisenby
|
78,806
|
41,722
|
9,868
|
C
|
27,216
|
20,160
|
7,056
|
|||||||||||||||||||||||||||
M.H.
Yokoyama & J.S. Venuti Family Trust dated 4/95
|
4,295
|
3,473
|
822
|
|||||||||||||||||||||||||||||||
Joe
Nitti
|
3,436
|
2,779
|
657
|
|||||||||||||||||||||||||||||||
Thomas
& Denise M. Nudo
|
77,396
|
62,584
|
14,802
|
|||||||||||||||||||||||||||||||
Alan
Platner
|
18,149
|
6,947
|
1,644
|
C
|
9,558
|
7,080
|
2,478
|
|||||||||||||||||||||||||||
David
Pudelsky & Nancy Pudelsky
|
21,657
|
8,344
|
1,973
|
C
|
11,340
|
8,400
|
2,940
|
|||||||||||||||||||||||||||
Louis
R. Reif
|
54,731
|
22,252
|
5,263
|
C
|
27,216
|
20,160
|
7,056
|
|||||||||||||||||||||||||||
Suzanne
Schiller
|
15,401
|
6,953
|
1,644
|
C
|
6,804
|
5,040
|
1,764
|
|||||||||||||||||||||||||||
George
L. Seward
|
8,591
|
6,947
|
1,644
|
|||||||||||||||||||||||||||||||
Jerome
Shinkay
|
8,597
|
6,953
|
1,644
|
|||||||||||||||||||||||||||||||
William
Silver
|
15,401
|
6,953
|
1,644
|
C
|
6,804
|
5,040
|
1,764
|
|||||||||||||||||||||||||||
Vernon
L. Simpson
|
8,591
|
6,947
|
1,644
|
|||||||||||||||||||||||||||||||
Lucile
Slocum
|
42,635
|
22,252
|
5,263
|
C
|
15,120
|
11,200
|
3,920
|
|||||||||||||||||||||||||||
Pershing
LLC as Custodian for Howard M. Tanning
|
84,571
|
34,768
|
8,223
|
C
|
41,580
|
30,800
|
10,780
|
|||||||||||||||||||||||||||
Carolyn
Taylor
|
43,463
|
27,815
|
6,578
|
C
|
9,072
|
6,720
|
2,350
|
|||||||||||||||||||||||||||
Michael
Weiser
|
200,601
|
2,781
|
657
|
B
|
189,206
|
119,901
|
28,000
|
|||||||||||||||||||||||||||
GunnAllen
Financial, Inc.
|
75,250
|
-
|
75,250
|
C
|
6,074
|
-
|
6,074
|
|||||||||||||||||||||||||||
Harris
Lydon (See
Series A Offering)
|
292,270
|
-
|
32,895
|
C
|
1,826
|
-
|
1,826
|
B
|
7,407
|
2,141
|
500
|
Name
|
Shares
Beneficially Owned Before Offering
|
No.
of Shares Issuable upon conversion of Series A
|
No.
of Shares Issuable upon Exercise of Warrants
|
Transaction
|
Shares
Beneficially Owned Before Offering
|
Common
Stock
|
No.
of Shares Issuable upon Exercise of Warrants
|
Transaction
|
Shares
Beneficially Owned Before Offering
|
Common
Stock
|
No.
of Shares Issuable upon Exercise of Warrants
|
|||||||||||||||||||||||
AB
Capital, L.P.
|
150,000
|
100,000
|
50,000
|
|||||||||||||||||||||||||||||||
Adams
Market Neutral, LLLP
|
75,000
|
50,000
|
25,000
|
|||||||||||||||||||||||||||||||
Fernando
Ahumada
|
107,466
|
66,667
|
33,333
|
A
|
7,466
|
5,333
|
2,133
|
|||||||||||||||||||||||||||
Jorge
Ahumada
|
59,332
|
33,333
|
16,667
|
A
|
9,333
|
6,666
|
2,666
|
|||||||||||||||||||||||||||
Balanced
Investment
|
220,833
|
125,000
|
62,500
|
A
|
48,666
|
13,333
|
5,333
|
|||||||||||||||||||||||||||
Alp
Benadrete
|
56,250
|
37,500
|
18,750
|
|||||||||||||||||||||||||||||||
Izzet
Benadrete
|
125,000
|
83,333
|
41,667
|
|||||||||||||||||||||||||||||||
Capretti
Grandi, LLC
|
1,375,000
|
833,333
|
416,667
|
|||||||||||||||||||||||||||||||
Tim
P. Cooper
|
50,000
|
33,333
|
16,667
|
|||||||||||||||||||||||||||||||
Russell
H. Ellison
|
25,000
|
16,667
|
8,333
|
|||||||||||||||||||||||||||||||
Boulevard
Georges
|
170,000
|
113,333
|
56,667
|
|||||||||||||||||||||||||||||||
Steven
T. Glass
|
62,500
|
41,667
|
20,833
|
|||||||||||||||||||||||||||||||
Ben
Heller
|
200,000
|
133,333
|
66,667
|
|||||||||||||||||||||||||||||||
Elliot
H. Herskowitz IRA Rollover
|
154,156
|
83,333
|
41,667
|
|||||||||||||||||||||||||||||||
Neil
Herskowitz IRA Rollover
|
162,434
|
83,333
|
41,667
|
|||||||||||||||||||||||||||||||
High
Glen Properties Limited
|
250,000
|
166,667
|
83,333
|
|||||||||||||||||||||||||||||||
David
Jaroslawicz
|
200,000
|
133,333
|
66,667
|
A
|
8,000
|
-
|
8,000
|
|||||||||||||||||||||||||||
Daniel
U. Kelves & BettyAnn Kelves
|
15,833
|
8,333
|
4,167
|
A
|
4,666
|
3,333
|
1,333
|
|||||||||||||||||||||||||||
Charles
Hartman King
|
62,500
|
41,667
|
20,833
|
|||||||||||||||||||||||||||||||
CSA
Biotechnology Fund II
|
2,916,667
|
1,666,667
|
833,333
|
|||||||||||||||||||||||||||||||
Klaus
Kretschmer
|
500,000
|
333,333
|
166,667
|
C
|
54,000
|
40,000
|
14,000
|
|||||||||||||||||||||||||||
Nicholas
B. Kronwall Trust Dated 11/12/69
|
25,000
|
16,667
|
8,333
|
A
|
11,416
|
3,333
|
1,333
|
C
|
11,516
|
5,000
|
1,750
|
|||||||||||||||||||||||
Brian
Lenz
|
53,571
|
16,667
|
8,333
|
|||||||||||||||||||||||||||||||
Javier
Livas
|
25,000
|
16,667
|
8,333
|
|||||||||||||||||||||||||||||||
Harris
Lydon (See
Series B Offering)
|
292,270
|
16,667
|
183,333
|
A
|
7,407
|
-
|
4,766
|
|||||||||||||||||||||||||||
Susan
and Harry Newton, JTWROS
|
125,000
|
83,333
|
41,667
|
A
|
41,500
|
2,000
|
8,000
|
C
|
41,500
|
2,000
|
8,000
|
|||||||||||||||||||||||
Mario
Pasquel and Begona Miranda
|
32,388
|
16,667
|
8,333
|
A
|
6,481
|
3,333
|
1,333
|
|||||||||||||||||||||||||||
Neal
Polan
|
62,500
|
41,667
|
20,833
|
|||||||||||||||||||||||||||||||
Elke
R de Ramirez
|
28,312
|
16,667
|
8,333
|
A
|
3,313
|
1,333
|
5,333
|
|||||||||||||||||||||||||||
Riverside
Contracting, LLC
|
402,156
|
250,000
|
125,000
|
A
|
40,922
|
6,666
|
2,626
|
C
|
40,922
|
20,000
|
7,000
|
|||||||||||||||||||||||
Robert
Roth
|
25,000
|
16,667
|
8,333
|
|||||||||||||||||||||||||||||||
Roberto
Segovia
|
27,004
|
15,000
|
7,500
|
A
|
6,490
|
2,666
|
1,066
|
|||||||||||||||||||||||||||
South
Ferry #2 LP
|
1,316,666
|
833,333
|
416,667
|
|||||||||||||||||||||||||||||||
Starlight
Investment Holdings Limited
|
250,000
|
166,667
|
83,333
|
|||||||||||||||||||||||||||||||
Tokenhouse
Trading PTE Ltd.
|
183,915
|
83,333
|
41,667
|
A
|
58,916
|
13,333
|
5,333
|
C
|
58,916
|
15,000
|
5,250
|
|||||||||||||||||||||||
Lindsay
A. Rosenwald
|
1,886,002
|
-
|
251,666
|
A
|
342,599
|
-
|
61,629
|
C
|
347,099
|
-
|
4,500
|
|||||||||||||||||||||||
Lindsay
A. Rosenwald
|
B
|
342,599
|
115,619
|
27,000
|
||||||||||||||||||||||||||||||
Karl
Ruggeberg
|
40,667
|
-
|
40,667
|
A
|
5,924
|
-
|
3,283
|
C
|
4,942
|
-
|
4,942
|
|||||||||||||||||||||||
Karl
Ruggeberg
|
B
|
5,924
|
2,141
|
500
|
||||||||||||||||||||||||||||||
Justin
Welling
|
1,667
|
-
|
1,667
|